Core Viewpoint - The announcement from the company indicates that three active pharmaceutical ingredients (APIs) have been approved by the National Medical Products Administration of China for use in marketed formulations, highlighting the company's growth in the pharmaceutical sector [1] Group 1: Product Approvals - The three APIs approved are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is used for treating severe amoebic infections of the intestine and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]
石四药集团(02005)：非诺贝特、非诺贝特酸胆硷、及磷酸左奥硝唑酯二钠已获批登记成为在上市制剂使用的原料药